Annual report
8129.TEDINET S100W4IU
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.52T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥1.48T | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥1.39T | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.21T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥18.9bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥19.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥20.7bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥21.8bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥19.2bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥28.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥30.8bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥19.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.6bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥19.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥20.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥722.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥773.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥715.3bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥702.4bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥683.2bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥465.9bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥524.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥256.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥249.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥242.9bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥237.4bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥86.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥133.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥78.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥128.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥88.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥26.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥59.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥9m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥4.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥9.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥680m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥680m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥313.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥320.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.7 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.77 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥284.22 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥286.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.67 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.97 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥4,099.71 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,969.2 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,623.81 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,415.5 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,364.65 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 35.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 7,609 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 7,572 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 7,699 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 7,785 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 7,732 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥15.6bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥12.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥13.0bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.3bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥11.4bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥3.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.6bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.3bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥16.2bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥16.0bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.9bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥13.1bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥242.6bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥267.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥253.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥254.8bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥260.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥92.1bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥117.4bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥150.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥150.1bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥152.3bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥154.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥160.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥74.9bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥121.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥218.73 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥203.27 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.32 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.91 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥145.29 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥198.34 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥182.03 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥127.91 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥52.22 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥133.57 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥65 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,400.68 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,387.4 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,271.65 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,191.82 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,275.25 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 62.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.0% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.5% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 73,025,942 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 76,431,342 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 193 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 192 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 192 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 224 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 227 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥8m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥58.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥58.9bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥53.5bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥2.3bn |
| Dispensing Pharmacyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥855m |
| Dispensing Pharmacyreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥891m |
| Dispensing Pharmacyreportable segment | employees | at 2025-03-31 | 2648 pure |
| Dispensing Pharmacyreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥95.6bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥95.5bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥22m |
| Dispensing Pharmacyreportable segment | segment assets | at 2025-03-31 | ¥58.7bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥852m |
| Medical Products Manufacturing And Salesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥166m |
| Medical Products Manufacturing And Salesreportable segment | employees | at 2025-03-31 | 102 pure |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥8.8bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2025-03-31 | ¥19.4bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥729m |
| Medical Products Retailreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Products Retailreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.7bn |
| Medical Products Retailreportable segment | employees | at 2025-03-31 | 4450 pure |
| Medical Products Retailreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.46T |
| Medical Products Retailreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.42T |
| Medical Products Retailreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥48.2bn |
| Medical Products Retailreportable segment | segment assets | at 2025-03-31 | ¥585.3bn |
| Medical Products Retailreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥19.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥1.58T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥1.52T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥58.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥669.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥21.3bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥923m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥58.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥58.3bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥93.6bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥2.9bn |
| Dispensing Pharmacyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥647m |
| Dispensing Pharmacyreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥903m |
| Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥93.8bn |
| Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥93.8bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥15m |
| Dispensing Pharmacyreportable segment | segment assets | at 2024-03-31 | ¥56.8bn |
| Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥157m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥162m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2024-03-31 | ¥19.3bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥755m |
| Medical Products Retailreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.2bn |
| Medical Products Retailreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| Medical Products Retailreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.42T |
| Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.38T |
| Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥48.7bn |
| Medical Products Retailreportable segment | segment assets | at 2024-03-31 | ¥598.3bn |
| Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥1.54T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥1.48T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥58.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥679.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥22.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,097
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)野 水 善 之 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)白 鳥 大 輔 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)髙 田 雅 代 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)非上場株式等の評価 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】（金融商品関係） | |
| Reference2 kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】（重要な会計上の見積り）１．市場価格のない非連結子会社株式の評価 | |
| Reference3 kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】（連結財務諸表作成のための基本となる重要な事項）４．会計方針に関する事項 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)野 水 善 之 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)白 鳥 大 輔 | |
| Cpa3 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)髙 田 雅 代 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)非上場株式等の評価 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】（重要な会計上の見積り）市場価格のない非連結子会社株式の評価 | |
| Same as kam for consolidated fskam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 1210274000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 1266171000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 1392117000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 1476712000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 1518495000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 10289000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 18182000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 19176000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 21787000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 20716000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 4989000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 13379000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 13630000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 20657000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 19844000000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 8027000000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 5701000000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 11592000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 20705000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 16160000000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 237405000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |